Loading...
Loading...
A report from Piper Jaffray reiterates its Overweight rating and raises its price target from $73 to $83 on Regeneron Pharmaceuticals
REGN.
The report states, “We expect EYLEA will compete well against Lucentis given the drug's lower price, similar efficacy with fewer monitoring visits and injections. Regeneron expects to end 2011 with >$800 million in cash to launch EYLEA, ZALTRAP in colorectal cancer and ARCALYST to prevent gout flares.”
REGN closed Friday at $49.81.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in